GLP-1 Based Combination Therapy for Obesity and Diabetes

GLP-1 Based Combination Therapy for Obesity and Diabetes

Bibliographic Details
Main Authors:	Young Hee Lee, Hee Won Lee, Hyung Jin Choi
Format:	Article
Language:	English
Published:	Korean Society for the Study of Obesity 2017-09-01
Series:	Journal of Obesity & Metabolic Syndrome
Online Access:	https://doi.org/10.7570/jomes.2017.26.3.155

Similar Items

Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
by: Young-Sun Lee, et al.
Published: (2016-01-01)

Glucolipotoxicity and GLP-1 secretion
by: Jung-Hee Hong, et al.
Published: (2021-08-01)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
by: Sara Heidarzadeh, et al.
Published: (2013-01-01)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
by: Roja Daliri, et al.
Published: (2013-01-01)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.
by: Niina Matikainen, et al.
Published: (2016-01-01)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
by: Jens Juul Holst
Published: (2021-05-01)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
by: Jens Juul Holst
Published: (2019-04-01)

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes
by: Neil Tanday, et al.
Published: (2021-05-01)

COMPARISON OF THE LEVELS OF C-REACTIVE PROTEIN, GLP-1 AND GLP-2 AMONG INDIVIDUALS WITH DIABETES, MORBID OBESITY AND HEALTHY CONTROLS: AN EXPLORATORY STUDY
by: Everton CAZZO, et al.

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
by: Mette Simone Aae Madsen, et al.
Published: (2019-10-01)

GLP-1 based therapeutics: Simultaneously combating T2DM and obesity
by: Kristy M Heppner, et al.
Published: (2015-03-01)

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes
by: Chia-Hung Lin, et al.
Published: (2015-01-01)

Review: The evolving world of GLP-1 agonist therapies for type 2 diabetes
by: Kevin C. R. Baynes
Published: (2010-06-01)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
by: Jinmi Lee, et al.
Published: (2012-08-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010-07-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Lisa M Neff, et al.
Published: (2010-07-01)

Obesity alters global response to ischemia and GLP-1 agonism
by: Sassoon, Daniel Jay
Published: (2016)

Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans
by: Martin Heni, et al.
Published: (2015-12-01)

Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin.
by: Iuliia V. Silko, et al.
Published: (2016-05-01)

The role of Leu260Phe polymorphism of the receptor gene to GLP-1 incretin in the pathogenesis of diabetes type 2 diabetes with obesity
by: Daria A. Skuratovskaia, et al.
Published: (2019-08-01)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
by: Lee SP, et al.
Published: (2019-06-01)

GLP-1 based therapies and disease course of inflammatory bowel disease
by: Marie Villumsen, et al.
Published: (2021-07-01)

Combined MSC and GLP-1 Therapy Modulates Collagen Remodeling and Apoptosis following Myocardial Infarction
by: Elizabeth J. Wright, et al.
Published: (2016-01-01)

GLP-1 secretion by microglial cells and decreased CNS expression in obesity
by: Kappe Camilla, et al.
Published: (2012-12-01)

South Asian Consensus Guideline: Use of GLP-1 analogue therapy in diabetes during Ramadan
by: Md Faruque Pathan, et al.
Published: (2012-01-01)

Antagonistic interaction between central glucagon-like Peptide-1 and oxytocin on diet-induced obesity mice
by: Jeonghoon Lee, et al.
Published: (2020-10-01)

Swedish diabetes patients’ experiences of using GLP-1 receptor agonists (GLP-1 RAs) : A qualitative interview study.
by: Ekenberg, Marie
Published: (2021)

The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes
by: Taylor R. Inman, et al.
Published: (2018-05-01)

The effects of twelve weeks of combined exercises on GLP-1 and insulin resistance in women with type 2 diabetes
by: Reihaneh Nejati, et al.
Published: (2019-05-01)

Synthesis and Evaluation of Optical and PET GLP-1 Peptide Analogues for GLP-1R Imaging
by: Babak Behnam Azad, et al.
Published: (2015-01-01)

Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies
by: Safia Costes, et al.
Published: (2021-05-01)

Role and development of GLP-1 receptor agonists in the management of diabetes
by: Chee&nbsp;W Chia, et al.
Published: (2009-05-01)

The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain
by: Choon Sang Bae, et al.
Published: (2017-11-01)

Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM)
by: Shengwu Ma, et al.
Published: (2017-04-01)

GLP-1/GLP-1R Signaling in Regulation of Adipocyte Differentiation and Lipogenesis
by: Jicui Chen, et al.
Published: (2017-06-01)

Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
by: Naichang Li, et al.
Published: (2012-01-01)

Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?
by: Chloé Amouyal, et al.
Published: (2016-01-01)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto′s thyroiditis
by: Yue Jin, et al.
Published: (2015-01-01)

Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis
by: Li Yang, et al.
Published: (2021-01-01)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
by: Stolar MW, et al.
Published: (2013-11-01)